Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
26 May 2020
26 May 2020
Historique:
received:
29
04
2020
accepted:
15
05
2020
entrez:
6
5
2022
pubmed:
27
5
2020
medline:
27
5
2020
Statut:
epublish
Résumé
The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is a key enzyme in pathways regulating tumor growth signaling, and recently gained interest as a promising anticancer drug target. Many SHP2 inhibitors are currently under development, including SHP099, which has shown potent anticancer activity at low concentrations
Identifiants
pubmed: 35520441
doi: 10.1039/d0ra03864d
pii: d0ra03864d
pmc: PMC9054207
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20073-20082Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Annu Rev Biomed Eng. 2020 Jun 4;22:1-24
pubmed: 32084319
Chem Rev. 2014 Nov 12;114(21):10940-75
pubmed: 25247843
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Sep-Oct;6(5):411-21
pubmed: 24723385
J Phys Chem B. 2014 Jun 26;118(25):7147-55
pubmed: 24911963
ACS Chem Biol. 2018 Mar 16;13(3):647-656
pubmed: 29304282
Biomaterials. 2010 Mar;31(8):2348-57
pubmed: 20004967
J Control Release. 2012 Apr 10;159(1):14-26
pubmed: 22154931
Langmuir. 2004 Jan 20;20(2):448-58
pubmed: 15743090
J Control Release. 2016 Sep 28;238:231-241
pubmed: 27288878
Molecules. 2016 Mar 28;21(4):372
pubmed: 27043500
ACS Appl Mater Interfaces. 2015 Jun 17;7(23):12882-93
pubmed: 25992843
Biomed Res Int. 2015;2015:198268
pubmed: 26582104
J Med Chem. 2016 Sep 8;59(17):7773-82
pubmed: 27347692
Carbohydr Polym. 2013 Apr 2;93(2):718-30
pubmed: 23499116
Cancer Res. 2017 Nov 1;77(21):5701-5705
pubmed: 28855209
Adv Drug Deliv Rev. 2011 Aug 14;63(9):730-47
pubmed: 21463658
J Med Chem. 2019 Feb 28;62(4):1781-1792
pubmed: 30688462
J Control Release. 2011 Oct 30;155(2):159-66
pubmed: 21699932
ACS Appl Mater Interfaces. 2014 Jun 11;6(11):8447-60
pubmed: 24745551
Exp Biol Med (Maywood). 2019 Apr;244(6):526-533
pubmed: 30897959
Cancer Cell. 2016 Aug 8;30(2):194-196
pubmed: 27505669
Bioconjug Chem. 2006 Jan-Feb;17(1):77-83
pubmed: 16417254
Chem Commun (Camb). 2019 Apr 23;55(34):4905-4908
pubmed: 30901006
Drug Deliv. 2010 Aug;17(6):365-75
pubmed: 20429844
Chem Rev. 1998 Jul 30;98(5):1755-1786
pubmed: 11848948
Biomaterials. 2017 Feb;117:54-65
pubmed: 27936417
Nature. 2016 Jul 7;535(7610):148-52
pubmed: 27362227
ACS Nano. 2014 Aug 26;8(8):8374-82
pubmed: 25100313
J Biomed Mater Res A. 2019 Jun;107(6):1324-1339
pubmed: 30719831
Small. 2010 Nov 5;6(21):2392-404
pubmed: 20925040
Langmuir. 2016 Nov 29;32(47):12552-12558
pubmed: 27280755
Eur J Med Genet. 2015 Oct;58(10):509-25
pubmed: 26341048
Ann Surg Oncol. 2008 Oct;15(10):2887-93
pubmed: 18636295
Leukemia. 2018 May;32(5):1246-1249
pubmed: 29568093
Eur J Pharm Biopharm. 2004 Jan;57(1):19-34
pubmed: 14729078
J Med Chem. 2014 Aug 14;57(15):6594-609
pubmed: 25003231
J Biomed Mater Res A. 2016 Jun;104(6):1408-24
pubmed: 26833891
Adv Drug Deliv Rev. 2013 Aug;65(9):1215-33
pubmed: 23673149
Acta Pharm Sin B. 2019 Mar;9(2):304-315
pubmed: 30972278